Published in NEJM, 2021
Results from the REMAP-CAP trial: IL-6ra interventions are superior to control for patients with severe COVID-19. A fully Bayesian, adaptive platform trial..
Recommended citation: The REMAP-CAP Investigators. (2021) Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N Engl J Med DOI: 10.1056/NEJMoa2100433 https://www.nejm.org/doi/full/10.1056/NEJMoa2100433